FDA Elevates OST to Super Office in CDRH
CDRH is pleased to announce that, effective immediately, the Office of Strategic Partnerships and Technology Innovation (OST) has been elevated to a Super Office within the Center.
CDRH is pleased to announce that, effective immediately, the Office of Strategic Partnerships and Technology Innovation (OST) has been elevated to a Super Office within the Center.
The FDA is taking steps to ensure that no matter where laboratory tests are made, patients and providers can trust that the results are accurate.
CDRH’s 2023 Annual Report captures a banner year for novel medical device authorizations, cybersecurity, mammography, digital health, and more.